Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:synthetic_anabolic-androgenic_steroid
gptkb:nandrolone_ester |
| gptkbp:activeIngredient |
gptkb:nandrolone
|
| gptkbp:administeredBy |
gptkb:physician
|
| gptkbp:ATCCode |
A14AB01
|
| gptkbp:CASNumber |
62-90-8
|
| gptkbp:chemicalClass |
19-nortestosterone derivative
|
| gptkbp:discoveredIn |
1950s
|
| gptkbp:eliminationHalfLife |
4 days (approximate)
|
| gptkbp:hasMolecularFormula |
C27H34O3
|
| gptkbp:legalStatus |
prescription only (varies by country)
|
| gptkbp:marketedAs |
1959
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
X (contraindicated)
|
| gptkbp:prohibits |
sports (WADA list)
|
| gptkbp:relatedTo |
gptkb:nandrolone_decanoate
|
| gptkbp:routeOfAdministration |
intramuscular injection
|
| gptkbp:sideEffect |
gynecomastia
fluid retention virilization |
| gptkbp:synonym |
gptkb:NPP
nandrolone phenpropionate |
| gptkbp:usedFor |
treatment of anemia
muscle wasting diseases |
| gptkbp:bfsParent |
gptkb:nandrolone
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
nandrolone phenylpropionate
|